Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
During a 48-week phase 2 obesity trial, patients on weekly doses of Retatrutide (8 mg and 12 mg) had average body weight losses of 22.8% and 24.2%, respectively
The lack of significant differences in well-being indices and anxiety and depression scores between the two groups may be attributable to numerous confounding psychological factors, strong patient heterogeneity, small sample size, and short follow-up duration
TNF-, tumor necrosis factor-alpha
This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching
What formulary tier is Ozempic on UnitedHealthcare
US$ 21.73
US$ 26.21
US$ 25.26
US$ 29.63
US$ 22.46
